Regulatory status of complementary medicine in Qatar: An update.

Integr Med Res

Ministry of Health, Cairo, Egypt.

Published: December 2022

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637887PMC
http://dx.doi.org/10.1016/j.imr.2022.100896DOI Listing

Publication Analysis

Top Keywords

regulatory status
4
status complementary
4
complementary medicine
4
medicine qatar
4
qatar update
4
regulatory
1
complementary
1
medicine
1
qatar
1
update
1

Similar Publications

Fluorogenic Tetrazine Bioorthogonal Probes for Advanced Application in Bioimaging and Biomedicine.

Chem Biomed Imaging

January 2025

Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging and Functional and Molecular lmaging Key Laboratory of Sichuan Province, West China Hospital of Sichuan University. Chengdu 610041, Sichuan, China.

A variety of bioorthogonal chemical tools have been developed and widely used in the study of biological phenomena in situ. Tetrazine bioorthogonal chemistry exhibits ultrafast reaction kinetics, excellent biocompatibility, and precise optical regulatory capabilities. Fluorogenic tetrazine bioorthogonal probes have achieved particularly diverse applications in bioimaging and disease diagnosis and treatment.

View Article and Find Full Text PDF

Osteosarcoma (OS) is a commonly observed malignant tumor in orthopedics that has a very poor prognosis. The endosomal sorting complex required for transport (ESCRT) is important for the development and progression of cancer and may be a significant target for cancer therapy. First, we built a prognostic signature using 7 ESCRT-related genes (ERGs) to predict OS patient prognosis.

View Article and Find Full Text PDF

Background: The Immunoglobulin Heavy Chain (IGH) genomic region is responsible for the production of circulating antibodies and warrants careful investigation for its association with COVID-19 characteristics. Multiple allelic variants within and across different IGH gene segments form a limited set of haplotypes. Previous studies have shown associations between some of these haplotypes and clinical outcomes of COVID-19.

View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a 5-year survival rate of 12%. It has two major molecular subtypes: classical and basal, regulated by the master transcription factors (MTFs) GATA6 and ΔNp63, respectively.

Objective: This study sought to uncover the transcriptional regulatory mechanisms controlling PDAC subtype identity.

View Article and Find Full Text PDF

The impact of operational trial approaches on representativeness: Comparison of decentralized clinical trial participants, conventional trial participants, and patients in daily practice.

Drug Discov Today

January 2025

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; Department of Clinical Pharmacy, Division Laboratory and Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands; Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland. Electronic address:

Decentralized clinical trial (DCT) approaches - in which trial activities are conducted at participants' homes - have the potential to improve representativeness. We present a study that compared the demographics and cardiovascular risk factors of participants from a DCT (ASCEND) and a conventional trial with a similar trial objective (POPADAD) to those of patients in daily practice. We adjudicate that there are relevant differences when comparing the participants of the conventional trial and the DCT, with the latter providing better representativeness in terms of age, insulin use, smoking status, and body mass index, whereas conventional trial participants were more representative in terms of biological sex.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!